These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11407398)

  • 1. Images in clinical medicine. Zidovudine myopathy.
    Chariot P
    N Engl J Med; 1993 Jun; 328(23):1675. PubMed ID: 11407398
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Gold R; Meurers B; Reichmann H
    N Engl J Med; 1990 Oct; 323(14):994. PubMed ID: 2402267
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV or zidovudine myopathy?
    Dalakas M
    Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
    Schröder JM; Bertram M; Schnabel R; Pfaff U
    Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV or zidovudine myopathy?
    Grau JM; Casademont J
    Neurology; 1994 Feb; 44(2):361; author reply 362-4. PubMed ID: 8309595
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
    Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
    Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine.
    Herzberg NH; Zorn I; Zwart R; Portegies P; Bolhuis PA
    Muscle Nerve; 1992 Jun; 15(6):706-10. PubMed ID: 1324428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
    Semino-Mora MC; Leon-Monzon ME; Dalakas MC
    Lab Invest; 1994 Jul; 71(1):102-12. PubMed ID: 7518879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
    Chariot P; Monnet I; Gherardi R
    Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
    Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
    Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
    Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine].
    Charton-Bain MC; Flamant M; Aubertin JM; Belair MF; Gilquin J; Kazatchkine M; Bruneval P
    Gastroenterol Clin Biol; 1997; 21(12):979-81. PubMed ID: 9587562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type B lactic acidosis in an AIDS patient treated with zidovudine.
    Aggarwal A; al-Talib K; Alabrash M
    Md Med J; 1996 Nov; 45(11):929-31. PubMed ID: 8942169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy.
    Scruggs ER; Dirks Naylor AJ
    Pharmacology; 2008; 82(2):83-8. PubMed ID: 18504416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitochondrial toxicity: a case of palpebral ptosis in a woman infected by HIV and treated with HAART including zidovudine].
    Zannou DM; Azon-Kouanou A; Bashi BJ; Gougounon A; Zinsou R; Adé G; Houngbè F
    Bull Soc Pathol Exot; 2009 May; 102(2):97-8. PubMed ID: 19583030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage.
    Dalakas MC; Leon-Monzon ME; Bernardini I; Gahl WA; Jay CA
    Ann Neurol; 1994 Apr; 35(4):482-7. PubMed ID: 8154877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of HIV-associated myopathy by zidovudine.
    Berger JR; Shebert R; Gregorios JB
    AIDS; 1991 Feb; 5(2):229-30. PubMed ID: 2031699
    [No Abstract]   [Full Text] [Related]  

  • 19. Mitochondria and HIV infection: the first decade.
    Cossarizza A; Troiano L; Mussini C
    J Biol Regul Homeost Agents; 2002; 16(1):18-24. PubMed ID: 12003168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy.
    Campos Y; Arenas J
    Ann Neurol; 1994 Oct; 36(4):680-1. PubMed ID: 7944307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.